Treatment with PPAR α agonist clofibrate inhibits the transcription and activation of srebps and reduces triglyceride and cholesterol levels in liver of broiler chickens

4Citations
Citations of this article
15Readers
Mendeley users who have this article in their library.

Abstract

PPARα agonist clofibrate reduces cholesterol and fatty acid concentrations in rodent liver by an inhibition of SREBP-dependent gene expression. In present study we investigated the regulation mechanisms of the triglyceride- and cholesterol-lowering effect of the PPARα agonist clofibrate in broiler chickens. We observed that PPARα agonist clofibrate decreases the mRNA and protein levels of LXRα and the mRNA and both precursor and nuclear protein levels of SREBP1 and SREBP2 as well as the mRNA levels of the SREBP1 (FASN and GPAM) and SREBP2 (HMGCR and LDLR) target genes in the liver of treated broiler chickens compared to control group, whereas the mRNA level of INSIG2, which inhibits SREBP activation, was increased in the liver of treated broiler chickens compared to control group. Taken together, the effects of PPARα agonist clofibrate on lipid metabolism in liver of broiler chickens involve inhibiting transcription and activation of SREBPs and SREBP-dependent lipogenic and cholesterologenic gene expression, thereby resulting in a reduction of the triglyceride and cholesterol levels in liver of broiler chickens.

Cite

CITATION STYLE

APA

Zhang, L., Li, C., Wang, F., Zhou, S., Shangguan, M., Xue, L., … He, D. (2015). Treatment with PPAR α agonist clofibrate inhibits the transcription and activation of srebps and reduces triglyceride and cholesterol levels in liver of broiler chickens. PPAR Research, 2015. https://doi.org/10.1155/2015/347245

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free